Related Experiment Video
Updated: Mar 29, 2026
Retroductal Nanoparticle Injection to the Murine Submandibular Gland
Published on: May 3, 2018
A clinically relevant retrograde intraductal injection (RIDI) for lipid nanoparticles-mediated base editing in the
Deepak Sahel1, Amita Tiyaboonchai2, Leslie Wakefield2
1Department of Pharmaceutical Sciences, College of Pharmacy, Robertson Life Sciences Building, Oregon State University, Portland, OR, USA.
None:
Gene therapy offers potential curative strategies for many pancreatic diseases, including diabetes and inherited pancreatitis. However, their clinical translation has been hindered by the lack of an effective delivery platform. Lipid nanoparticles (LNPs) are established as a leading non-viral delivery system for nucleic acids; however, their tropism is limited to the liver following systemic administration. In this study, we evaluated retrograde intraductal injection (RIDI), a clinically relevant and routinely performed endoscopic technique, as a direct delivery route for LNPs into pancreatic tissue. RIDI of Cre mRNA-loaded LNPs resulted in the transfection of approximately 47% of acinar cells, leading to robust recombination. Extending this approach to gene editing, we observed ~20-30% of gene editing and 5% base editing in mouse models. Collectively, these findings establish RIDI as a viable strategy for pancreas-targeted LNP administration, highlighting its potential to enable gene therapy and gene editing in pancreatic diseases.
